|
|Section2= |Section3= }} Mavoglurant (AFQ056) is an experimental drug candidate for the treatment of fragile X syndrome. It exerts its effect as an antagonist of the metabotropic glutamate receptor 5 (mGLU5). Mavoglurant is under development by Novartis and is currently in Phase II and Phase III clinical trials.〔 Phase IIb/III dose finding and evaluation trials for fragile X-syndrome have been discontinued by the end of 2014.〔http://www.fraxa.org/novartis-discontinues-development-mavoglurant-afq056-fragile-x-syndrome/〕 Otherwise, it would have been the first drug to treat the underlying disorder instead of the symptoms of fragile X syndrome.〔(【引用サイトリンク】 AFQ056 drug improves symptoms in Fragile X patients: Study )〕 Mavoglurant is also in Phase II clinical trials for Levodopa-induced dyskinesia. In 2007, Norvartis had conducted a clinical study to assess its ability of reducing cigarette smoking, but no results had been published up till now. Currently Novartis is conducting a clinical trial with this drug on obsessive compulsive disorder. Novartis discontinued development of mavoglurant for fragile X syndrome in April 2014 following disappointing trial results.〔(【引用サイトリンク】 author = FRAXA )〕 ==See also== * Basimglurant * MTEP 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Mavoglurant」の詳細全文を読む スポンサード リンク
|